Dr. Britten is Associate Clinical Professor in the Department of Medicine, hematology
/Oncology at UCLA. She is also a practicing physician at that institution, as well as at the Dumont-UCLA Liver Cancer Center in the area of Head and Neck Oncology. She serves as Co-Associate Director of the JCCC signal transduction
and Therapeutics Program Area. She received her M.D. in 1992 from the University of Toronto, Faculty of Medicine. From 1993–1995, she did her internship and residency in internal medicine at the University of Western Ontario. She then worked under fellowship grants, first in medical oncology at the University of British Columbia, Vancouver (1995–1997), then in drug development at the University of Texas Medical School at San Antonio (1997–1999). Her current work and clinical practice encompass research and treatment of breast and gastrointestinal
Year STOP CANCER Award was received:
Details of research performed with funding from STOP CANCER:
Dr. Carolyn Britten's research focuses on targeted anti-cancer therapies. She is studying signal transduction
inhibitors and anti-angiogenesis
agents in patients with advanced malignancies and is also conducting clinical trials involving hepatocellular
cancer and breast cancer.
Results of research: Dr. Britten has conducted clinical trials of drug therapies for hepatocellular and breast cancers. These trials have yielded data on the safety, tolerability, and efficacy of the drugs on advanced malignancies.